Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up

Cornea

Volumn 28, Issue 1, 2009, Pages 89-92

  Odorcic, Silvia ^a   Keystone, Edward C ^a,b   Ma, Joseph J K ^a,c,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c NORTH YORK GENERAL HOSPITAL   (Canada)

^d Herzig Eye Institute   (Canada)

^e NONE   (Canada)

Author keywords

Corneal perforation; Deep venous thrombosis; Infliximab; Peripheral ulcerative keratitis; Tumor necrosis factor a inhibitor

Indexed keywords

INFLIXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; PREDNISONE;

AGED; ARTICLE; CASE REPORT; CATARACT EXTRACTION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CORNEA PERFORATION; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INFUSION; KERATITIS; MALE; PRIORITY JOURNAL; REMISSION; SKIN DEFECT; STEROID THERAPY; TUMOR NECROSIS; ULCER; VISUAL ACUITY; CATARACT; CORNEA ULCER; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; LENS IMPLANTATION; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHACOEMULSIFICATION; TREATMENT OUTCOME; VEIN THROMBOSIS; WOUND HEALING;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CATARACT; CATARACT EXTRACTION; CORNEAL ULCER; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; KERATITIS; LENS IMPLANTATION, INTRAOCULAR; MALE; PHACOEMULSIFICATION; PREDNISONE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VENOUS THROMBOSIS; VISUAL ACUITY; WOUND HEALING;

EID: 62149131126     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318181a84f     Document Type: Article

References (22)

1. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. 1984;91:1253-1263.
2. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists. Preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007;27:399-413.
3. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor a blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356.
4. Atchia II, Kidd E, Bell RWD. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol. 2006;12:291-293.
5. Thomas JW, Pflugfelder SC. Therapy of progressive rheumatoid arthritisassociated corneal ulceration with infliximab. Cornea. 2005;24:742-744.
6. Hernandez-Illas M, Tozman E, Fulcher S, et al. Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens. 2004;30:2-5.
7. Schering-Plough Canada Inc. Our Products [Schering-Plough Canada Web site]. August 17, 2007. Available at: http://www.schering-plough.ca/ english/our%20products/products/default.asp?s = 1#inflam. Accessed November 30, 2007.
8. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358: 295-296.
9. Munoz-Fernandez S, Hidalco V, Fernandez MJ, et al. Effect of infliximab on threatening panuveitis in Behcet's disease [letter]. Lancet. 2001; 358:1644.
10. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Care Res. 2001;45:252-257.
11. Paranjothy B, Shunmugam M, MacKenzie J, et al. Peripheral ulcerative keratitis in pityriasis rubra pilaris. Eye. 2007;21:1001-1002.
12. Freidlin J, Wong IG, Acharya N. Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis. Br J Ophthalmol. 2007;91:1414.
13. Cheung CM, Murray PJ, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89:1542.
14. Ahmadi-Simab K. Successful therapy of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. 2005;64: 1087-1088.
15. Puli SR, Benage DD. Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn's disease. Am J Gastroenterol. 2003;98:939-940.
16. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis. Arch Ophthalmol. 2005;123: 903-912.
17. Mortimore M, Gibson PR. Early Australian experience with infliximab, a chimeric antibody against tumor necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? Intern Med J. 2001;31:146-150.
18. Yazici R. Infliximab in the treatment of rheumatoid arthritis (RA): referral patterns, response to treatment and adverse events in a real world setting. Annual European Congress of Rheumatology, European League Against Rheumatism, EULAR, Prague, Czech Republic, June13-16, 2001. Abstract FRI 0009.
19. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
20. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357:1874-1876.
21. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure. Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
22. Agarwal PK, Gallaghar M, Murphy E, et al. Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker. Indian J Ophthalmol. 2007;55:230-232.